PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for High Performance Computing, Joint Engineering Research Center for Health Big Data Intelligent Analysis Technology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.\', \'Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen Third People\'s Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China.\', \'Shenzhen Laboratory of Human Antibody Engineering, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, University City of Shenzhen, Shenzhen, China.\', \'CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.\', \'School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.\', \'University of Chinese Academy of Sciences, Shijingshan District, Beijing, China.\', \'Institute of Toxicology, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.\', \'Department of Computer Science, Georgia State University, Atlanta, Georgia, United States of America.\', \'Department of Pathology, School of Medicine, Shenzhen University, Shenzhen, China.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1371/journal.pcbi.1008489
?:hasPublicationType
?:journal
  • PLoS computational biology
is ?:pmid of
?:pmid
?:pmid
  • 33382685
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 3.097
?:rankingScore_hIndex
  • 138
?:title
  • A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all